Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
OncoCyte Corporation (OCX) had Receiveable Turnover of 1.17 for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$1.88M |
|
$-60.93M |
|
$1.14M |
|
$0.74M |
|
$62.92M |
|
$-61.04M |
|
$0.38M |
|
$-60.66M |
|
$-60.66M |
|
$-60.66M |
|
$-60.66M |
|
$-60.66M |
|
$-60.66M |
|
$-61.04M |
|
$-59.48M |
|
13.07M |
|
13.07M |
|
$-4.66 |
|
$-4.66 |
|
| Balance Sheet Financials | |
$11.76M |
|
$3.57M |
|
$23.32M |
|
$35.08M |
|
$7.28M |
|
-- |
|
$40.08M |
|
$47.35M |
|
$-12.27M |
|
$-26.88M |
|
$-12.27M |
|
17.45M |
|
| Cash Flow Statement Financials | |
$-20.71M |
|
$-0.51M |
|
$20.43M |
|
$11.13M |
|
$10.34M |
|
$-0.80M |
|
$1.75M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.62 |
|
-- |
|
-- |
|
-- |
|
-- |
|
39.34% |
|
-3245.14% |
|
-3245.14% |
|
-3161.99% |
|
-3225.04% |
|
-3239.02% |
|
$-21.23M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
2.78 |
|
|
Receiveable Turnover |
1.17 |
313.00 |
|
494.24% |
|
225.67% |
|
-172.92% |
|
494.24% |
|
$-0.70 |
|
$-1.62 |
|
$-1.58 |
|